Company
Clarus Therapeutics Holdings, Inc.
Headquarters: Northbrook, IL, United States
CEO: Dr. Robert E. Dudley Ph.D.
Clarus Therapeutics Holdings, Inc. Categories
United States
languages
Healthcare
languages
Drug Manufacturers—General
United States Healthcare
United States Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Pfizer
|
$287.63 B |
|
AbbVie
|
$285.80 B |
|
Merck
|
$281.30 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Stocks & Indices
Clarus Therapeutics Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CRXT